See the DrugPatentWatch profile for lurbinectedin

There is limited information available regarding the safety and risks of lurbinectedin use during pregnancy, as human studies are lacking [1]. However, animal studies have shown that lurbinectedin can cause embryo-fetal toxicity [1].

Lurbinectedin is a type of antineoplastic agent, which is a class of drugs that are designed to inhibit or prevent the growth and spread of cancer cells [1]. It is currently approved for the treatment of metastatic small cell lung cancer in adults [1].

According to the manufacturer's prescribing information, lurbinectedin can cause fetal harm when administered to a pregnant woman [1]. The manufacturer also states that women of reproductive potential should use effective contraception during treatment with lurbinectedin and for at least 6 months after the last dose [1].

It is important to note that the use of lurbinectedin during pregnancy is not recommended unless the potential benefit to the mother outweighs the potential risk to the fetus [1].

In summary, the risks of lurbinectedin use during pregnancy are not well understood due to a lack of human studies. However, animal studies have shown that lurbinectedin can cause embryo-fetal toxicity. The manufacturer's prescribing information states that lurbinectedin can cause fetal harm and recommends that women of reproductive potential use effective contraception during treatment and for at least 6 months after the last dose. The use of lurbinectedin during pregnancy is not recommended unless the potential benefit to the mother outweighs the potential risk to the fetus.

Sources:

* [1] DrugPatentWatch.com. Lurbinectedin. <https://www.drugpatentwatch.com/drugs/lurbinectedin>